Erminia Mascitelli - Academia.edu (original) (raw)

Uploads

Papers by Erminia Mascitelli

Research paper thumbnail of Extracorporeal life support for management of refractory cardiac or respiratory failure: initial experience in a tertiary centre

Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2010

Introduction: Extracorporeal Life Support (ECLS) and extracorporeal membrane oxygenation (ECMO) h... more Introduction: Extracorporeal Life Support (ECLS) and extracorporeal membrane oxygenation (ECMO) have been indicated as treatment for acute respiratory and/or cardiac failure. Here we describe our first year experience of inhospital ECLS activity, the operative algorithm and the protocol for centralization of adult patients from district hospitals.

Research paper thumbnail of Results of isolated lower limb perfusion for loco-regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases

Journal of Surgical Oncology, 2011

This study was conducted to assess the safety and efficacy of our modified ILP treatment with bor... more This study was conducted to assess the safety and efficacy of our modified ILP treatment with borderline true hyperthermia and high melphalan concentration in stage III lower limb melanoma. Between March 1990 and December 2006, 91 consecutive patients were given ILP treatment. Forty three patients were treated with double L-PAM bolus combined with D-actinomicin; 48 patients were treated with additional L-PAM bolus alone. The mean follow-up period is 68.5 months. The acute regional toxicity occurred with grade II (54%), III (38%), IV (2.1%). The systemic toxic effects were present with transitory hematological disorders. Complete response (CR) rate was observed in 89.2% of stage IIIA-IIIAB unexcised IT-mets. The overall limb recurrent disease in stage III was 39%. In patients with CR recurrent rate occurred in 44% with a mean limb recurrence-free interval (LRFI) of 23.8 months. Distant metastases was attained with a mean time of 29.2 months. After CR, the interval was 32.1 months. The 5-year survival rate was 45%; in patients with CR, was 48%. Our procedure is an important therapeutic option. The results suggest a marked local control of the recurrent disease. The LRFI is longer than for those treated with other treatment schedules.

Research paper thumbnail of Toxicity and morbility after isolated lower limb perfusion in 242 chemo-hyperthermal treatments for cutaneous melanoma. The experience of the Tuscan Reference Centre

Journal of Experimental & Clinical Cancer Research, 2008

The aim of this retrospective study was to assess the results concerning the regional and systemi... more The aim of this retrospective study was to assess the results concerning the regional and systemic toxicity and complications in 242 chemo-hyperthermal treatments (HILPs) for lower limb melanoma.

Research paper thumbnail of Extracorporeal membrane oxygenation for influenza A (H1N1): experience in a regional referral center

Research paper thumbnail of Extracorporeal life support for management of refractory cardiac or respiratory failure: initial experience in a tertiary centre

Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2010

Introduction: Extracorporeal Life Support (ECLS) and extracorporeal membrane oxygenation (ECMO) h... more Introduction: Extracorporeal Life Support (ECLS) and extracorporeal membrane oxygenation (ECMO) have been indicated as treatment for acute respiratory and/or cardiac failure. Here we describe our first year experience of inhospital ECLS activity, the operative algorithm and the protocol for centralization of adult patients from district hospitals.

Research paper thumbnail of Results of isolated lower limb perfusion for loco-regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases

Journal of Surgical Oncology, 2011

This study was conducted to assess the safety and efficacy of our modified ILP treatment with bor... more This study was conducted to assess the safety and efficacy of our modified ILP treatment with borderline true hyperthermia and high melphalan concentration in stage III lower limb melanoma. Between March 1990 and December 2006, 91 consecutive patients were given ILP treatment. Forty three patients were treated with double L-PAM bolus combined with D-actinomicin; 48 patients were treated with additional L-PAM bolus alone. The mean follow-up period is 68.5 months. The acute regional toxicity occurred with grade II (54%), III (38%), IV (2.1%). The systemic toxic effects were present with transitory hematological disorders. Complete response (CR) rate was observed in 89.2% of stage IIIA-IIIAB unexcised IT-mets. The overall limb recurrent disease in stage III was 39%. In patients with CR recurrent rate occurred in 44% with a mean limb recurrence-free interval (LRFI) of 23.8 months. Distant metastases was attained with a mean time of 29.2 months. After CR, the interval was 32.1 months. The 5-year survival rate was 45%; in patients with CR, was 48%. Our procedure is an important therapeutic option. The results suggest a marked local control of the recurrent disease. The LRFI is longer than for those treated with other treatment schedules.

Research paper thumbnail of Toxicity and morbility after isolated lower limb perfusion in 242 chemo-hyperthermal treatments for cutaneous melanoma. The experience of the Tuscan Reference Centre

Journal of Experimental & Clinical Cancer Research, 2008

The aim of this retrospective study was to assess the results concerning the regional and systemi... more The aim of this retrospective study was to assess the results concerning the regional and systemic toxicity and complications in 242 chemo-hyperthermal treatments (HILPs) for lower limb melanoma.

Research paper thumbnail of Extracorporeal membrane oxygenation for influenza A (H1N1): experience in a regional referral center

Log In